Skip to main navigation

BioAtla, Inc logo

preloader
BioAtla, Inc logo
  • Overview
  • News & Events
    • News Releases
    • Events and Presentations
  • Governance
    • Governance Overview
    • Board of Directors
    • Management
    • Committee Composition
  • Financials
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • Stock
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

News Releases

Date  
5/11/22
First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer
5/4/22
BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress
4/8/22
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
3/1/22
BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
1/10/22
BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors
logo-footer

BioAtla® is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics™ (CAB) platform exploits the unique microenvironment of diseased tissue to more effectively target cancer.

BIOATLA®

  • Technology
  • CAB Portfolio
  • Appendix

COMPANY

  • About
  • Team
  • Careers
  • News

LEGAL

  • Privacy Policy
  • Site Map
  • Expanded Access

GET IN TOUCH

  • Contact
  • Corporate Headquarters +1 858-558-0708

FOLLOW US

  • LinkedIn
  • Copyright © 2022 BioAtla®, Inc. All rights reserved